Indinavir

By F. Wenzel. University of California, Riverside. 2018.

Comparison of pioglitazone and metformin efficacy using homeostasis model assessment effective indinavir 400mg. Effects of the PPAR(gamma) agonist pioglitazone on lipoprotein 6 metabolism in patients with type 2 diabetes mellitus discount indinavir 400 mg otc. Thiazolidinedione use generic indinavir 400 mg line, 5 fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers 6 serum HDL cholesterol. Lipoprotein effects of different thiazolidinediones in 4 clinical practice. A systematic review of drug therapy to delay or prevent type 2 diabetes. Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. Thiazolidinediones for diabetes mellitus: Considerations for reimbursements by third-party payers. Disease 2 Management and Health Outcomes 2004; 12 (6):363-75. Therapeutic potential of thiazolidinediones as anticancer agents. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 -- 5 results of a pilot study. Thiazolidinediones, peripheral oedema and congestive heart failure: What is the evidence? Effect of pioglitazone compared with metformin on glycemic control and 2 indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. Impact of adjunctive thiazolidinedione therapy on blood lipid levels 5 and glycemic control in patients with type 2 diabetes. Mechanisms and relevance of idiosyncratic drug reactions. Improvement in Autonomic Function with Rosiglitazone in Type 2 Diabetes. Improvement of cardiovascular risk markers by pioglitazone is 2 independent from glycemic control: results from the pioneer study. Severe but reversible 6 Thiazolidinediones Page 126 of 193 Final Report Update 1 Drug Effectiveness Review Project cholestatic liver injury after pioglitazone therapy. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates 2 endothelial dysfunction independent of glucose control. The combined effect of triple therapy with rosiglitazone, metformin, and insulin 2 aspart in type 2 diabetic patients. Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes—a study in Indians. Economic model of first-line drug strategies to achieve 5 recommended glycaemic control in newly diagnosed type 2 diabetes mellitus. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes 6 mellitus that is poorly controlled with glibenclamide monotherapy. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of 5 prior antidiabetic drug regimen. Novel actions of thiazolidinediones on vascular function and exercise capacity. Normalization of 1 impaired glucose tolerance with rosiglitazone. Investigacion Medica Internacional 2000; 27 (1):9-13. Metformin monotherapy for type 2 diabetes mellitus Cochrane Database of 2 Syst Rev 2005; 3:3. The effect of 5 rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone. Combined thiazolidinedione-insulin therapy: should we be 5 concerned about safety? Hepatotoxicity with thiazolidinediones: is it a class effect? Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 6 diabetes after failure of two oral drugs: Efficacy, safety, and cost analysis.

R adiation:C ontrolled-clinicaltrials Screened/ W ith drawn/ A uth or cheap indinavir 400 mg on line, Eligible/ L ostto fu/ Y ear Enrolled A nalyz ed R esults A ctive-controlled trials Sykes N R /66/66 N R Com pleteorm ajorcontrolof em esis(0-2em etic episodes)onday1 indinavir 400 mg,O vsC : 1997 93 indinavir 400mg on line. R adiation:C ontrolled-clinicaltrials A uth or, Y ear A dverse events C om m ents A ctive-controlled trials Sykes N odeathsoccurredduring studyperiodandnosignificantdifferenceinlevelsof AE s 1997 betweenO andC. L essdrowsinessforO thanC,butp= N S U K Priestm an A lldata givenas O vs M 1990 deaths:6ptsvs4pts,p = N R (nonethoughttoberelatedtoantiem etic therapy) Priestm an severeheadacheandvertigo:1ptvs0pt,p = N R 1989 F eversandnightsweats:0ptvs1pt,p = N R N ochangesinclinicalchem istry,renalfunctionof hem atologicalparam etersthatwere consideredtreatm entrelatedforeitherdrug. R T = radioth erapy;O DT = orallydisintegratingtablets;B M T = bonemarrow transplantation;TB I= totalbodyirradiation Antiemetics Page 298 of 492 Final Report Update 1 Drug Effectiveness Review Project Evidence Table 8. Q uality assessm ents ofth e radiationcontrolled-clinicaltrials InternalValidity A llocation O utcom e A uth or, R andom iz ation concealm ent G roups sim ilarat Eligibility criteria assessors C are provider Patient Y ear adequate? C om parative trials Spitz er2000 Y es N R Y es Y es Placebo-controlled trials Bey 1996 N R N R Y es Y es N otreported Y es Y es F ranz en1996 Y es N R Y es forradioth erapy Y es N otreported Y es Y es regimens;unknownforoth er demograph ic/prognostic factors because th ey were N R Antiemetics Page 299 of 492 Final Report Update 1 Drug Effectiveness Review Project Evidence Table 8. Q uality assessm ents ofth e radiationcontrolled-clinicaltrials InternalValidity R eporting ofattrition, L oss to follow-up: Intention-to-treat(ITT) A uth or, crossovers,adh erence,and differential/ analysis; Post-random iz ation Y ear contam ination h igh IfN o:% analyz ed exclusions Q uality R ating C om parative trials Spitz er2000 Y es,N R ,N R ,N R Placebo-controlled trials Bey 1996 Y es,N R ,N R ,N R N one Y es N o F air F ranz en1996 Y es,N R ,N R ,N R N one N o;98. Q uality assessm ents ofth e radiationcontrolled-clinicaltrials A uth or, Y ear F unding C om parative trials Spitz er2000 Placebo-controlled trials Bey 1996 H oech stM arionR oussel F ranz en1996 G laxo W ellcome Antiemetics Page 301 of 492 Final Report Update 1 Drug Effectiveness Review Project Evidence Table 8. Q uality assessm ents ofth e radiationcontrolled-clinicaltrials InternalValidity A llocation O utcom e A uth or, R andom iz ation concealm ent G roups sim ilarat Eligibility criteria assessors C are provider Patient Y ear adequate? L anciano 2001 N R N R N o;various differences in Y es N otreported Y es Y es radiationtreatment L eBourgeois 1999 U nclear;"block N R U nclear;only provided Y es N otreported Y es Y es balanced" baseline ch aracteristics for 415 (27. Q uality assessm ents ofth e radiationcontrolled-clinicaltrials InternalValidity R eporting ofattrition, L oss to follow-up: Intention-to-treat(ITT) A uth or, crossovers,adh erence,and differential/ analysis; Post-random iz ation Y ear contam ination h igh IfN o:% analyz ed exclusions Q uality R ating Placebo-controlled trials,cont. Q uality assessm ents ofth e radiationcontrolled-clinicaltrials A uth or, Y ear F unding Placebo-controlled trials,cont. L anciano 2001 N R ,4th auth orfrom Smith K line Beech am L eBourgeois 1999 G laxo W ellcome Spitz er1994 G laxo,Inc. Tiley and Powles N R 1992 Antiemetics Page 304 of 492 Final Report Update 1 Drug Effectiveness Review Project Evidence Table 8. Q uality assessm ents ofth e radiationcontrolled-clinicaltrials InternalValidity A llocation O utcom e A uth or, R andom iz ation concealm ent G roups sim ilarat Eligibility criteria assessors C are provider Patient Y ear adequate? A ctive-controlled trials Prentice 1995 N R N R Y es Y es N otreported Y es Y es Sykes 1997 N R N R N R ;baseline ch aracteristics Y es N otreported Y es Y es were notpresented or discussed Priestman1990 N R N R Y es Y es N otreported Y es Y es Priestman1989 Priestman1993 N R N R Y es Y es N otreported Y es Y es Antiemetics Page 305 of 492 Final Report Update 1 Drug Effectiveness Review Project Evidence Table 8. Q uality assessm ents ofth e radiationcontrolled-clinicaltrials InternalValidity R eporting ofattrition, L oss to follow-up: Intention-to-treat(ITT) A uth or, crossovers,adh erence,and differential/ analysis; Post-random iz ation Y ear contam ination h igh IfN o:% analyz ed exclusions Q uality R ating A ctive-controlled trials Prentice 1995 N R ,N R ,N R ,N R N R Y es N o F air Sykes 1997 N R ,N R ,N R ,N R N R U nknown,no information U nknown Poor aboutnumberofpatients analyz ed Priestman1990 Y es,N R ,N R ,N R N one N o,84. Q uality assessm ents ofth e radiationcontrolled-clinicaltrials A uth or, Y ear F unding A ctive-controlled trials Prentice 1995 Smith K line Beech am Sykes 1997 G laxo L aboratories,Inc. Priestman1990 N R ,5th auth orfrom G laxo Priestman1989 G roupR esearch L imited Priestman1993 N R ,3rd auth orfrom G laxo G roupR esearch L imited Antiemetics Page 307 of 492 Final Report Update 1 Drug Effectiveness Review Project Evidence Table 9. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or Y ear A llow oth er R un-in/ Setting Design Exclusioncriteria Intervention m edication W ash out A dults Dolasetronvs. O ndansetron B irm ingh am D BR CT U nderthecareof am entalhealth-careprovider,physical D olasetron12m g iv R escuem edicationwas N o/N o 2006 Parallel statusASA classIII orhigher,pregnant,taking O ndansetron4m g iv allowed(determ inedby m edicationswith antiem etic propertieswithin48hours anesthesiaprovider) beforesurgery,presenting forinpatientsurgery,requiring adm issiontothehospitalforsurgicalreasons,not receiving generalanesthesia B rowning D BR CT Ptsex cludedif theywere<18,pregnant,receivedand D olasetroniv12. Erh an D B,R CT ASA classIII-IV;aged>70years;BM I >30;Prenancy; G roup 1:0. Antiemetics Page 308 of 492 Final Report Update 1 Drug Effectiveness Review Project Evidence Table 9. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or A ge/ Screened/ W ith drawn/ Y ear G ender/ Eligible/ L ostto fu/ Setting Eth nicity Enrolled A nalyz ed O th erpopulationch aracteristics A dults Dolasetronvs. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or Y ear Setting R esults A dverse Events A dults Dolasetronvs. O ndansetron B irm ingh am D olasetronvsO ndansetron N R 2006 Satisfactionwith m edication(VAS Score,0-100m m ):70. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or Y ear Setting C om m ents A dults Dolasetronvs. O ndansetron B irm ingh am 2006 B rowning PACU nursesallowedtoadm inisterrescueantiem eticsaccording topostoperativeanesthesiaorders,if theydeterm ineditwasneeded,if thept 2004 ex periencedpersistentnauseafor≥15m inutes,had≥1em etic episode,orif theptsrequestedm edication. Studyresultswereinnarrativeform SingleCenter only,with theex ceptionof how m anypatientswereinthestudy,andhow m anypergroup receivedspinalnarcotics. Analysesof em etic episodesboth inthePACU orin24h postsurgerywerefound nottodiffersignificantlybetweengroups. Thesam eresultswerefoundform eannum eric nauseaintensityscoresatanytim e,ptsatisfaction scores,andsideeffects. Erh an 2008 SingleCenter Antiemetics Page 311 of 492 Final Report Update 1 Drug Effectiveness Review Project Evidence Table 9. Preventionofpostoperative nauseaand vom iting:H ead-to-h ead trials A uth or Y ear A llow oth er R un-in/ Setting Design Exclusioncriteria Intervention m edication W ash out K ush wah a Com parati G astrointestinaldisorders,pregnancyorm enstruation, A)Placebo Prem edicatedwith oral N R /N R 2007 veStudy historyof m otionsicknessorprevioushistoryof PO N V, B)G ranisetron40m cg/kg alpraz olam 0.

purchase indinavir 400 mg with amex

Newer antiplatelet agents 45 of 98 Final Update 2 Report Drug Effectiveness Review Project In 20 332 patients with recent ischemic stroke who participated in the good-quality 42 PRoFESS trial discount 400 mg indinavir overnight delivery, the finding of noninferiority of the fixed-dose combination of extended-release dipyridamole plus aspirin over clopidogrel for the primary outcome of recurrent stroke was consistent in subgroups of patients with obesity (8 buy discount indinavir 400mg line. One fair-quality discount 400mg indinavir amex, head-to-head trial that compared clopidogrel 75 mg and ticlopidine 200 mg in Japanese patients with prior stroke for 52 weeks provided insufficient data to determine how the relative difference between the 2 drugs was impacted for the outcome of any recurrent 41 cardiovascular events. When multivariate analysis was performed using combined data from the clopidogrel and ticlopidine groups, the presence of diabetes (adjusted hazard ratio, 2. No comparison of clopidogrel and ticlopidine in patient subgroups based on diabetes or hyperlipidemia status was reported, however. Indirect evidence 21 In a subset analysis of CURE, patients with diabetes had a lower incidence of the first primary outcome on clopidogrel plus aspirin than placebo plus aspirin (14. Likewise, patients without diabetes also had a lower incidence of the first primary outcome with clopidogrel plus aspirin than placebo plus aspirin (7. Patients with diabetes had higher event rates than nondiabetics but within the diabetic group, those on clopidogrel plus aspirin showed a benefit compared to placebo plus aspirin. In several prespecified subgroup analyses using the primary endpoint in the 23 CHARISMA trial, patients with and without a history of diabetes, hypertension, hypercholesterolemia, stroke, prior coronary artery bypass graft surgery or percutaneous coronary intervention, or prior myocardial infarction were evaluated. In addition to these groups, current smoking, body mass index, gender, and age were also included in the analyses. All subgroups, except patients with no history of myocardial infarction or coronary artery bypass graft surgery and patients with a 30 or greater body mass index score fared better with clopidogrel plus aspirin than aspirin alone as represented by the hazard ratios for each subgroups (see also gender section). Diabetes was prevalent in 42% of the study population. Hazards ratios for other subgroups mentioned in the text including patients with and without peripheral arterial disease or prior transient ischemic attack were not depicted. In ESPS-2, rates of first stroke (fatal and nonfatal) were evaluated in subgroups of patients with noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus. In patients with noninsulin-dependent diabetes mellitus, compared to taking aspirin alone, rate of first stroke was slightly higher with the fixed-dose combination of extended-release dipyridamole plus aspirin (12. However, comparative statistics within subgroups were not provided. The analysis used external stroke validated Newer antiplatelet agents 46 of 98 Final Update 2 Report Drug Effectiveness Review Project models from the Framingham Study and the Stroke Prognostic Instrument II (SPI-2) to estimate the risk. Estimated risk categories based on the ESPS-2 baseline variables were converted to risk scores using these 2 models. Compared with aspirin alone, treatment with extended-release dipyridamole/aspirin resulted in substantial relative hazard reductions for stroke within some of the specific risk factor subgroups including those younger than 70 years of age, those with hypertension, prior myocardial infarction, prior stroke or transient ischemic attack, and any prior cardiovascular disease, and current smokers. The greatest relative hazard reduction for stroke or vascular events was among patients who already had experienced a stroke or transient ischemic attack before the qualifying event. Those who already had at least 2 prior events (transient ischemic attack/stroke), of which 1 was the qualifying events for inclusion into the study, had the least incidence of subsequent stroke compared to those who had only 1 prior event (the qualifying transient ischemic attack/stroke). Patients with a history of myocardial infarction who were treated with extended-release dipyridamole/aspirin had a 36. Patients with any prior cardiovascular disease had a 27. Patients taking extended-release dipyridamole/aspirin had a greater relative hazard reduction for the endpoint of combined stroke or vascular events among those patients with a prior stroke or transient ischemic attacks, previous myocardial infarction, 72 and among current smokers. The annual risk for recurrent stroke among those treated with aspirin increased from 3. Relative hazard reductions favored the combination of aspirin plus extended- release dipyridamole in all the subgroups, and were greatest for the high-risk Framingham group and the moderate-risk SPI-2 subgroup. Similar results were observed for stroke or vascular events. The post-hoc analysis suggested that extended-release dipyridamole/aspirin provides greater benefit for patients with a higher risk for stroke, as per predicted stroke probabilities. Newer antiplatelet agents 47 of 98 Final Update 2 Report Drug Effectiveness Review Project Table 6. Stroke or vascular event rates in ESPS-2: extended-release 72 dipyridamole/aspirin or aspirin monotherapy Number With extended- With a of release aspirin Relative hazard P a Risk group subjects dipyridamole/aspirin only reduction (CL) values Annual stroke rates Framingham stroke risk score 1453 3. Abbreviations: CL, confidence limit For Framingham Study model: the 10-year stroke probability (primarily first stroke) is low (≤0.

order indinavir 400mg with amex

No significant laboratory abnormalities were reported purchase 400 mg indinavir amex. Low One RCT reported no adverse events were observed in any patient and there were no dropouts for postpubertal adolescents with IBS-C treated with tegaserod discount indinavir 400 mg on-line. N/A No evidence is available on docusate calcium indinavir 400mg cheap, docusate sodium, lactulose, lubiprostone, and psyllium Key Question 3: Comparative Safety Chronic Low Lactulose vs. PEG 3350: constipation or One poor quality RCT reported lower rates of flatus and abdominal IBS-C in adults pain, but higher rates of diarrhea for PEG. PEG 3350: constipation or Two poor quality studies provided mixed evidence about differences IBS-C in children of adverse events between lactulose and psyllium. Key Question 4: Subgroups Efficacy and Chronic constipation: harms based on N/A One pooled data analysis of lubiprostone published as an abstract sex only. N/A No evidence is available on docusate calcium, docusate sodium, lactulose, PEG 3350, psyllium or tegaserod. Constipation associated with IBS: N/A No evidence is available on docusate calcium, docusate sodium, lactulose, lubiprostone, PEG 3350, psyllium or tegaserod. Efficacy and Chronic constipation: harms based on N/A Two pooled data analyses of lubiprostone in patients > 65 years age published as abstracts only. N/A No evidence is available on docusate calcium, docusate sodium, lactulose, PEG 3350, psyllium or tegaserod. Constipation associated with IBS: N/A No evidence Efficacy and No evidence harms based on race/ethnicity Efficacy and No evidence harms based on co-morbidities Constipation Drugs Page 73 of 141 Final Report Drug Effectiveness Review Project ADDENDUM 76 As this report was going to press, the first full text study on lubiprostone was published. In this RCT, 129 patients with chronic constipation were randomized to lubiprostone (24, 48, or 72 mcg/day) or placebo. During the 21 days of follow-up, lubiprostone improved spontaneous bowel movement (SBM) rates in a dose-dependent manner. The most common adverse events were nausea (33%), headache (11%), and diarrhea (11%). Adverse events also occurred in a dose- dependent manner. Overall, 62% - 70% of patients in the lubiprostone groups experienced at least one adverse event (compared with 39% in the placebo group). Because lubiprostone 72 mcg/d led to higher rates of adverse events, the authors concluded that no clear risk-to-benefit advantage existed compared with lubiprostone 48 mcg/d. Constipation Drugs Page 74 of 141 Final Report Drug Effectiveness Review Project REFERENCES 1. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. An evidence-based approach to the management of chronic constipation in North America. Epidemiology of constipation in North America: a systematic review. Stewart WF, Liberman JN, Sandler RS, Woods MS, Stemhagen A, Chee E, et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, Coyne K. The health-related quality of life and economic burden of constipation. Chronic constipation--is the work- up worth the cost? Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. In: Drossman DA, Corazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, et al. Rome III: The Functional Gastrointestinal Disorders, 3rd edition. Irritable bowel syndrome: classification and conceptualization. American Gastroenterological Association Medical Position Statement: guidelines on constipation. Public Health Advisory: Tegaserod maleate (marketed as Zelnorm).

Indinavir
8 of 10 - Review by F. Wenzel
Votes: 221 votes
Total customer reviews: 221

 

Leave a Reply